Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

Dasatinib was approved at 100 mg once daily for imatinib‐resistant or ‐intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180‐034 (NCT00123474) study. Here we present the final 7‐year analysis of this pivotal study, the longest follow‐up to da...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Hematol
Autori principali: Shah, Neil P., Rousselot, Philippe, Schiffer, Charles, Rea, Delphine, Cortes, Jorge E., Milone, Jorge, Mohamed, Hesham, Healey, Diane, Kantarjian, Hagop, Hochhaus, Andreas, Saglio, Giuseppe
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5094534/
https://ncbi.nlm.nih.gov/pubmed/27192969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24423
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi